| DC10149 |
TM5275 sodium salt
Featured
|
TM5275 is an orally available, potent and selective inhibitor of PAI-1 that delivers antithrombotic benefits devoid of bleeding effect in nonhuman primates. |
|
| DC10374 |
TM5441
Featured
|
TM5441 is a novel orrally active TAP-1 antagonist. |
|
| DC10083 |
UK-371804
Featured
|
UK-371804 is a potent and selective uPA inhibitor with excellent enzyme potency (Ki 10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin). |
|
| DC12039 |
ZK824859
Featured
|
ZK824859 is a selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. |
|
| DC11078 |
Cenupatide
Featured
|
Cenupatide is an urokinase plasminogen activator receptor (uPAR) inhibitor drug candidate. Cenupatide inhibits uPAR binding to the formyl peptide receptors (FPRs) can improve kidney lesions in a rat model of streptozotocin (STZ)-induced diabetes. Cenupati |
|
| DC42471 |
Angstrom6 |
Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling. |
|
| DC45370 |
UK122 |
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion. |
|
| DC46325 |
Diaplasinin |
Diaplasinin (PAI-749) is a plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 295 nm. Antithrombotic efficacy. |
|
| DC47408 |
28-O-β-D-Glucopyranosyl pomolic acid |
28-O-β-D-Glucopyranosyl pomolic acid is a urokinase plasminogen activator inhibitor with IC50 at 37.82 μM. |
|
| DC47409 |
ACT001 |
ACT001 is orally active PAI-1 inhibitor by inhibiting the phosphorylation of PI3K and AKT. ACT001 inhibits the phosphorylation of STAT3 and PD-L1 expression by directly binding to STAT3. ACT001, a fumarate salt form of Micheliolide, can cross the blood-brain barrier. ACT001 has potent anti-glioblastoma (GBM) activity and immunomodulatory effects.
|
|
| DC50259 |
Geodin |
Geodin, a fungal metabolite, shows antibacterial activity. Geodin also is an inhibitor of plasminogen activator inhibitor- 1 (PAI-1). |
|
| DC70093 |
WX-UK1 |
WX-UK1 (UKI-1) is a small synthetic serine protease uPA (urokinase-type plasminogen activator) inhibitor that blocks tumor cell invasion, metastasis and primary tumor growth. |
|
| DC73776 |
IPR-3011 |
IPR3011 is a small-molecule uPAR-uPA protein-protein interaction inhibitor with Ki of 2.4 uM. |
|
| DC73777 |
WX-293 |
WX-293 is a highly selective small-molecule inhibitor of urokinase-type plasminogen activator (uPA) with Ki of 2.4 uM. |
|
| DC73778 |
WX-340 |
WX-340 is a highly specific and selective, peptidic cyclic competitive inhibitor of urokinase-type plasminogen activator (uPA) with Ki of 12 and 170 nM for human and mouse uPA, respectively, inhibit 10 Units of human uPA with IC50 of 90 nM. |
|
| DC74593 |
ACT001(DMAMCL) |
ACT001(DMAMCL, dimethylaminomicheliolide) is a PAI-1 inhibitor and exerts antitumor effects on neuroblastoma (NB) both in vitro and in vivo. It also exerts synergistic effects in combination with cisplatin through the inhibition of the PAI-1/PI3K/AKT pathway. |
|
